London School of Hygiene and Tropical Medicine, London, UK.
National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London, UK.
BMJ. 2021 Jul 14;374:n1592. doi: 10.1136/bmj.n1592.
To assess the association between learning disability and risk of hospital admission and death from covid-19 in England among adults and children.
Population based cohort study on behalf of NHS England using the OpenSAFELY platform.
Patient level data were obtained for more than 17 million people registered with a general practice in England that uses TPP software. Electronic health records were linked with death data from the Office for National Statistics and hospital admission data from NHS Secondary Uses Service.
Adults (aged 16-105 years) and children (<16 years) from two cohorts: wave 1 (registered with a TPP practice as of 1 March 2020 and followed until 31 August 2020); and wave 2 (registered 1 September 2020 and followed until 8 February 2021). The main exposure group consisted of people on a general practice learning disability register; a subgroup was defined as those having profound or severe learning disability. People with Down's syndrome and cerebral palsy were identified (whether or not they were on the learning disability register).
Covid-19 related hospital admission and covid-19 related death. Non-covid-19 deaths were also explored.
For wave 1, 14 312 023 adults aged ≥16 years were included, and 90 307 (0.63%) were on the learning disability register. Among adults on the register, 538 (0.6%) had a covid-19 related hospital admission; there were 222 (0.25%) covid-19 related deaths and 602 (0.7%) non-covid deaths. Among adults not on the register, 29 781 (0.2%) had a covid-19 related hospital admission; there were 13 737 (0.1%) covid-19 related deaths and 69 837 (0.5%) non-covid deaths. Wave 1 hazard ratios for adults on the learning disability register (adjusted for age, sex, ethnicity, and geographical location) were 5.3 (95% confidence interval 4.9 to 5.8) for covid-19 related hospital admission and 8.2 (7.2 to 9.4) for covid-19 related death. Wave 2 produced similar estimates. Associations were stronger among those classified as having severe to profound learning disability, and among those in residential care. For both waves, Down's syndrome and cerebral palsy were associated with increased hazards for both events; Down's syndrome to a greater extent. Hazard ratios for non-covid deaths followed similar patterns with weaker associations. Similar patterns of increased relative risk were seen for children, but covid-19 related deaths and hospital admissions were rare, reflecting low event rates among children.
People with learning disability have markedly increased risks of hospital admission and death from covid-19, over and above the risks observed for non-covid causes of death. Prompt access to covid-19 testing and healthcare is warranted for this vulnerable group, and prioritisation for covid-19 vaccination and other targeted preventive measures should be considered.
评估英格兰成年人和儿童中学习障碍与因 COVID-19 住院和死亡风险之间的关联。
代表英格兰国民保健署使用 OpenSAFELY 平台进行的基于人群的队列研究。
为使用 TPP 软件的英格兰注册全科医生的 1700 多万人获得了患者水平数据。电子健康记录与国家统计局的死亡数据和 NHS 二级使用服务的住院数据相关联。
来自两个队列的成年人(16-105 岁)和儿童(<16 岁):第 1 波(截至 2020 年 3 月 1 日在 TPP 实践中注册并随访至 2020 年 8 月 31 日);和第 2 波(2020 年 9 月 1 日注册并随访至 2021 年 2 月 8 日)。主要暴露组由普通实践学习障碍登记册中的人员组成;定义了一个亚组,即那些有严重或严重学习障碍的人。确定了唐氏综合征和脑瘫患者(无论是否在学习障碍登记册上)。
与 COVID-19 相关的住院和 COVID-19 相关的死亡。还探讨了非 COVID-19 死亡。
对于第 1 波,包括 14312023 名年龄≥16 岁的成年人,其中 90307 人(0.63%)在学习障碍登记册上。在登记册上的成年人中,有 538 人(0.6%)因 COVID-19 相关住院;有 222 人(0.25%)COVID-19 相关死亡和 602 人(0.7%)非 COVID 死亡。在未登记的成年人中,有 29781 人(0.2%)因 COVID-19 相关住院;有 13737 人(0.1%)COVID-19 相关死亡和 69837 人(0.5%)非 COVID 死亡。学习障碍登记册上成年人的第 1 波危险比(经年龄、性别、种族和地理位置调整)为 COVID-19 相关住院的 5.3(95%置信区间 4.9 至 5.8)和 COVID-19 相关死亡的 8.2(7.2 至 9.4)。第 2 波产生了类似的估计值。在被归类为严重至严重学习障碍的人和在住宿护理中的人,关联更为强烈。对于两个波,唐氏综合征和脑瘫都与这两种事件的风险增加有关;唐氏综合征的程度更大。非 COVID 死亡的风险比也遵循类似的模式,关联较弱。儿童也表现出类似的相对风险增加模式,但 COVID-19 相关死亡和住院治疗很少见,反映出儿童的低事件发生率。
与非 COVID 死亡原因导致的死亡相比,学习障碍者因 COVID-19 住院和死亡的风险明显更高。应确保为这一弱势群体及时获得 COVID-19 检测和医疗保健,并应考虑为 COVID-19 疫苗接种和其他有针对性的预防措施提供优先接种。